TNF Pharmaceuticals Inc. (Nasdaq: TNFA) has successfully closed a $7 million private placement financing. The transaction involved the sale of 7,000 shares of convertible preferred stock at $1,000 per share, convertible into 1,400,000 shares of common stock at an initial conversion price of $5.00. The deal was led by the company's largest strategic stockholder with significant participation from existing stockholders. Accompanying the preferred stock are warrants to purchase an additional 1,400,000 shares of common stock at the same conversion price. The funding aims to support TNF's key development milestones, particularly in advancing their innovative light-based computing accelerator for blockchain technology. Executive Chairman Joshua Silverman expressed confidence in the company's value proposition and future strategies.